Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 3780

1.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
2.

[The sodium pump could constitute a new target to combat glioblastomas].

Lefranc F, Mijatovic T, Kiss R.

Bull Cancer. 2008 Mar;95(3):271-81. doi: 10.1684/bdc.2008.0597. French.

PMID:
18390407
3.

[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].

Lefranc F.

Bull Mem Acad R Med Belg. 2007;162(5-6):331-8. French.

PMID:
18405003
4.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
5.

The role of autophagy in sensitizing malignant glioma cells to radiation therapy.

Zhuang W, Qin Z, Liang Z.

Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):341-51. Review.

7.

Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.

Lefranc F, Facchini V, Kiss R.

Oncologist. 2007 Dec;12(12):1395-403. doi: 10.1634/theoncologist.12-12-1395. Review.

8.

Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.

Lefranc F.

Acta Neurochir (Wien). 2009 Feb;151(2):109-12. doi: 10.1007/s00701-009-0185-9. Epub 2009 Feb 5.

PMID:
19194651
9.

Evidence of galectin-1 involvement in glioma chemoresistance.

Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V.

Toxicol Appl Pharmacol. 2008 Jun 1;229(2):172-83. doi: 10.1016/j.taap.2008.01.009. Epub 2008 Jan 29.

PMID:
18313712
10.

Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.

Lena A, Rechichi M, Salvetti A, Bartoli B, Vecchio D, Scarcelli V, Amoroso R, Benvenuti L, Gagliardi R, Gremigni V, Rossi L.

J Transl Med. 2009 Feb 5;7:13. doi: 10.1186/1479-5876-7-13.

11.

Molecularly targeted therapy for malignant glioma.

Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN.

Cancer. 2007 Jul 1;110(1):13-24. Review.

12.

Therapeutic exploitation of apoptosis and autophagy for glioblastoma.

Kögel D, Fulda S, Mittelbronn M.

Anticancer Agents Med Chem. 2010 Jul;10(6):438-49. Review.

PMID:
20879985
13.
15.

Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.

Hargrave D.

Br J Neurosurg. 2009 Aug;23(4):351-63. doi: 10.1080/02688690903158809. Review.

PMID:
19637006
16.

Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.

Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J.

Molecules. 2009 Apr 16;14(4):1561-77. doi: 10.3390/molecules14041561. Review.

17.

Radiochemotherapy of malignant glioma in adults. Clinical experiences.

Kortmann RD, Jeremic B, Weller M, Plasswilm L, Bamberg M.

Strahlenther Onkol. 2003 Apr;179(4):219-32. Review.

PMID:
12707711
18.

Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells.

Kim EH, Sohn S, Kwon HJ, Kim SU, Kim MJ, Lee SJ, Choi KS.

Cancer Res. 2007 Jul 1;67(13):6314-24.

19.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
20.

The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.

Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS.

Cancer Res. 2007 Oct 15;67(20):9809-16.

Items per page

Supplemental Content

Write to the Help Desk